Cancer News and Research

RSS

Cancer begins in your cells, which are the building blocks of your body. Normally, your body forms new cells as you need them, replacing old cells that die. Sometimes this process goes wrong. New cells grow even when you don't need them, and old cells don't die when they should. These extra cells can form a mass called a tumor. Tumors can be benign or malignant. Benign tumors aren't cancer while malignant ones are. Cells from malignant tumors can invade nearby tissues. They can also break away and spread to other parts of the body.

New computational approach enhances the performance of bioinformatics tools

UVA Health researchers have created an innovative tool to assist scientists in distinguishing signals from noise as they investigate the genetic underpinnings of cancer and other disorders.

24 Nov 2022

Novel approach increases the protein production efficiency of synthetic mRNAs

A group of synthetic biologists at the Hong Kong University of Science and Technology (HKUST) recently figured out a way to improve the efficiency of synthetic mRNA protein production by up to tenfold.

24 Nov 2022

New effort to generate high quality reference genomes for 1,000 known species of euglenoids

The Euglena International Network (EIN) (https://euglenanetwork.org/), founded in 2020, is a global consortium of hundreds of scientists around the world with the collective goal of supporting euglenoid science through collaborative and integrative omics between academics and industry.

23 Nov 2022

The influence of genes and small molecules on personal disease risk

Each individual has a unique chemical fingerprint. Small molecules in the blood, like fats or sugars, have a significant impact on how the human body responds to stress, which diseases people are predisposed to, and how serious an illness will be.

23 Nov 2022

Molecular motion of “undruggable” proteins reveals drug-binding sites

“Undruggable” proteins, whose structures and roles in disease are known but who appear unable to be targeted by drugs that will bind to them, present some of the hardest problems in disease treatment.

23 Nov 2022

The critical role of amino acid sensing pathways in driving colorectal cancer

A dietary modification may be essential to improving colon cancer treatment, according to research from the University of Michigan Rogel Cancer Center.

22 Nov 2022

Revealing the functional significance of DDX41 in great detail

The DDX41 gene encodes the nuclear enzyme DEAD-box-type RNA helicase. Hematopoietic malignancies are caused by DDX41 mutations. However, the mechanism behind the development of this malignancy remains unknown.

21 Nov 2022

Applying “programmable molecular scissors” to combat COVID-19 infection

As an approach that could be used to create a new class of antiviral drugs, synthetic biology was used by Cambridge scientists to artificially create enzymes programmed to attack the genetic code of SARS-CoV-2 and eliminate the virus.

17 Nov 2022

Revealing cancer development in people carrying inherited BRCA1 mutations

Researchers from Weill Cornell Medicine have discovered that people who inherit a mutant copy of the BRCA1 gene may develop mutations and cancer due to error-prone DNA replication and repair.

16 Nov 2022

New study figures out which patients will react to immunotherapy

According to a new study, patients with head and neck cancer who have more chromosome 9 genetic material in their cancer cells survive three times longer after accepting immunotherapy than patients who have less of it.

From New York University (NYU) 15 Nov 2022

Researchers create genetic 'devices' to perform computations like artificial neural circuits

Bringing together concepts from electrical engineering and bioengineering tools, Technion and MIT scientists collaborated to produce cells engineered to compute sophisticated functions – "biocomputers" of sorts.

15 Nov 2022

NIH funds research on mRNA vaccines to stop cancer development

The National Cancer Institute at the National Institutes of Health has awarded a multidisciplinary team of Weill Cornell Medicine researchers a five-year $5.7 million grant to support a center dedicated to creating messenger RNA (mRNA) vaccines to prevent the development of cancer in at-risk groups.

15 Nov 2022